Herantis Pharma Oyj
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HRPMF research report →
Companywww.herantis.com
Herantis Pharma Oyj, a biotech company, engages in the development of disease-modifying CDNF-based therapies for Parkinson's disease (PD). Its lead product in pipeline includes HER-096, an advanced small and synthetic chemical peptidomimetic version of the active parent as the preclinical xCDNF candidate for the treatment of PD and other neurodegenerative diseases; and recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF), a biological protein that is in Phase I study in patients with PD. The company was incorporated in 2008 and is based in Espoo, Finland.
- CEO
- Antti Vuolanto D.Sc. (Tech)
- IPO
- 2018
- Employees
- 10
- HQ
- Espoo, FI
Price Chart
Valuation
- Market Cap
- $59.47M
- P/E
- -6.41
- P/S
- 0.00
- P/B
- -25.14
- EV/EBITDA
- -7.71
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -21354.84%
- ROIC
- -363.20%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-4,939,000 · -1864.94%
- EPS
- $-0.24 · -1572.39%
- Op Income
- $-5,026,000
- FCF YoY
- -41.18%
Performance & Tape
- 52W High
- $3.51
- 52W Low
- $3.51
- 50D MA
- $3.51
- 200D MA
- $3.51
- Beta
- 0.43
- Avg Volume
- 0
Get TickerSpark's AI analysis on HRPMF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our HRPMF Coverage
We haven't published any research on HRPMF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate HRPMF Report →